Figure 1.
Diagram showing the contribution of KRAS and BRAF to the EGFR pathway.
Activating mutations in both BRAF and KRAS will result in EGFR independent cell proliferation and hence resistance to anti-EGFR antibody treatment.
Figure 2.
Sample flow for CAST PCR using automated extraction to allow results to be generated in <24 hours.
Table 1.
Summary of results.
Table 2.
A concordance matrix for KRAS for mutations included in both the Therascreen and castPCR assays.
Table 3.
Results for castPCR and Therascreen for each case included in the study.